Fierce BioBiotech
Gilead loosens ties to Arcus after TIGIT dream finally ends in phase 3 failure
Summary
Gilead and Arcus' domvanalimab, one of the last anti-TIGIT antibodies still standing, has failed another trial—leading Gilead to pull further away from their once wide-ranging collaboration.
Gilead and Arcus' domvanalimab, one of the last anti-TIGIT antibodies still standing, has failed another trial—leading Gilead to pull further away from their once wide-ranging collaboration.